vinblastine,Dacarbazine,nivolumab,doxorubicin
bms
['nivo']
t) with recent exciting data from &amp; of concurrent nivo-avd (in mostly fit) older hl pts w/ pfs rates &gt;85% &amp; os &gt;95%, we are uniquely positioned to continue to improve outcomes &amp; concurrently mitigate toxicity, which will take a concerted, collaborative effort
AV-Chancellor @RutgersBHS; AD @RutgersCancer; MedDir/Onc Lead @RWJBarnabas; EiC @e_JHaem; Lym VChair @eaonc; @lymphoma SAB; 🇺🇸🇺🇦🇵🇱🇮🇹🇩🇪🇬🇷 #BillsMafia